<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552655</url>
  </required_header>
  <id_info>
    <org_study_id>BREAC-AUT</org_study_id>
    <nct_id>NCT01552655</nct_id>
  </id_info>
  <brief_title>Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT</brief_title>
  <acronym>BREAC-AUT</acronym>
  <official_title>Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to elucidate the value of dual-time-point PET/CT in the&#xD;
      recurrence of breast cancer and to determine whether the method is better than the modalities&#xD;
      used in the standard work up.&#xD;
&#xD;
      150 patients with suspected breast cancer recurrence will be included. All patients will&#xD;
      undergo dual-time-point PET/CT, CT of thorax and upper abdomen and bone scintigraphy. After&#xD;
      completion of the examinations the early and the late PET/CT scan will be compared with each&#xD;
      other, the diagnostic CT-scan and the bone scintigraphy. A verification of suspicious&#xD;
      findings will be done by biopsy, if the area is accessible. If a biopsy cannot be obtained,&#xD;
      the presence of recurrence will be verified with additional imaging follow-up to ensure the&#xD;
      highest possible confidence. Sensitivity, specificity, accuracy, negative and positive&#xD;
      predictive value (NPV/PPV) will be calculated for each modality (incl. early and late&#xD;
      PET/CT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic value of dual-time point 18FDG PET/CT in recurrent breast cancer</measure>
    <time_frame>2 years</time_frame>
    <description>The sensitivity and specificity of dual-time point 18FDG PET/CT will be compared to conventional imaging modalities usually used in the work up of patients with suspected recurrent breast cancer. In this case CT of thorax and upper abdomen and bone scintigraphy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic value of early and late 18FDG PET/CT respectively in recurrent breast cancer</measure>
    <time_frame>2 years</time_frame>
    <description>The sensitivity and specificity of early (60 min post injection) and late (180 min post injection) 18FDG PET/CT respectively in patients with suspected recurrent breast cancer.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Breast Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Dual-time PET/CT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dual-time PET/CT (low-dose)</intervention_name>
    <description>4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.</description>
    <arm_group_label>Dual-time PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical suspected recurrence of breast cancer&#xD;
&#xD;
          -  Blood glucose level less than 8,0 mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disqualified patients&#xD;
&#xD;
          -  Other malignancies&#xD;
&#xD;
          -  &lt; 18 years&#xD;
&#xD;
          -  &lt; 50 kg&#xD;
&#xD;
          -  &gt; 90 kg&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Patients with permanent address outside of the Region of Southern Denmark&#xD;
&#xD;
          -  Estimated inability to collaborate&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malene Hildebrandt, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Nuclear Medicine, Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Funen</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Kirsten Falch</investigator_full_name>
    <investigator_title>Medical Technologist</investigator_title>
  </responsible_party>
  <keyword>Dual-time PET/CT</keyword>
  <keyword>Breast cancer recurrence</keyword>
  <keyword>Bone scintigraphy</keyword>
  <keyword>CT thorax upper abdomen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

